AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering

Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) announced a proposed rights offering expected to raise up to $12.0 million if fully subscribed. Record Date is Feb 4, 2026; Subscription Period is Feb 5–Feb 23, 2026. Each holder receives one non-transferable Subscription Right to buy one unit at $1,000 per unit. Each unit consists of one share of Series G Convertible Preferred Stock and warrants to purchase 1,492 shares of common stock.

Preferred shares are convertible at an initial conversion price of $1.34 per share; each warrant exercisable at $1.34 for five years. Over-subscription privileges apply. CEO Thomas K. Equels indicated non-binding intent to participate. Net proceeds intended for clinical/manufacturing expenses and partial debt repayment.

Positive

• Potential gross proceeds of $12.0 million
• Over-subscription privilege may increase subscribed proceeds
• Net proceeds allocated to clinical and manufacturing expenses

Negative

• Convertible preferred and warrants create potential shareholder dilution
• Subscription Rights are non-transferable, limiting marketability
• Short subscription window (Feb 5–Feb 23, 2026) pressures investor decision timeline

Key Figures

Rights offering gross proceeds: $12 million Subscription price per unit: $1,000 per unit Warrants per unit: 1,492 warrants +5 more

8 metrics

Rights offering gross proceeds $12 million Assuming full subscription of the announced rights offering

Subscription price per unit $1,000 per unit Rights offering subscription price for each unit

Warrants per unit 1,492 warrants Each unit includes warrants for 1,492 common shares

Conversion price $1.34 per share Initial conversion price for Series G Convertible Preferred Stock

Preferred stated value $1,000 Stated value per share of Series G Convertible Preferred Stock

Warrant exercise price $1.34 per share Exercise price for warrants included in each unit

Warrant term 5 years Warrants exercisable from issuance through five years

Registered units 12,000 Units Units registered in Form S-1 targeting the rights offering

Market Reality Check

Price: $1.20 Vol: Volume 111,083 is below 2...

low vol

$1.20 Last Close

Volume Volume 111,083 is below 20-day average of 187,122, suggesting a modest pre-news participation. low

Technical Shares at $1.26 are trading below the $2.56 200-day moving average, indicating a longer-term downtrend.

Peers on Argus

AIM gained 7.69% while peers were mixed: HCWB up 7.36%, PMCB up 2.74%, TNFA down...

1 Up

AIM gained 7.69% while peers were mixed: HCWB up 7.36%, PMCB up 2.74%, TNFA down 9.72%, NCNA down 1.53%, BCLI flat. Combined with scanner data showing only one biotech peer in momentum, this points to a stock-specific reaction.

Previous Offering Reports

2 past events · Latest: Jul 31 (Negative)

Same Type Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Jul 31	Public offering closing	Negative	-4.3%	Closing of $8.0M public equity offering with accompanying long- and short-term warrants.
Jul 29	Public offering pricing	Negative	-56.3%	Pricing of $8.0M equity offering with common stock and warrants at $4.00 per share.

Pattern Detected

Prior AIM equity offerings were followed by single-day share price declines, indicating a history of negative reactions to dilution-related news.

Recent Company History

Over the past six months, AIM has repeatedly tapped capital markets and highlighted Ampligen’s oncology potential. Prior offering events in July 2025 raised $8.0M and saw shares fall 4.26% and 56.25% the next day. More recently, AIM reported Q3 2025 results with cash of $2.4M and a net loss of $(3.3M), while reinforcing its strategic focus on pancreatic cancer trials. Today’s rights offering update fits this ongoing effort to fund the Ampligen program and strengthen the balance sheet.

Historical Comparison

offering

+30.3 %

Average Historical Move

Historical Analysis

In the past year, AIM’s offering-related announcements produced an average move of 30.25%, with both prior events leaning negative. Today’s rights offering update continues this reliance on equity financing for liquidity and trial funding.

Typical Pattern

AIM has moved from traditional public offerings in <b>July 2025</b> to a rights offering structure, leveraging existing holders while its broader <b>$100M</b> shelf provides additional flexibility for future financings.

Regulatory & Risk Context

Active S-3 Shelf · $100 million

Shelf Active

Active S-3 Shelf Registration 2025-06-27

$100 million registered capacity

AIM has an effective Form S-3/A shelf filed on June 27, 2025, allowing issuance of up to $100 million of various securities. This rights offering draws on that capital-markets flexibility and, alongside prior usage via a 424B5 in July 2025, underscores ongoing dilution capacity for existing shareholders.

Market Pulse Summary

This announcement outlines a rights offering that could raise up to $12 million via Series G Convert...

Analysis

This announcement outlines a rights offering that could raise up to $12 million via Series G Convertible Preferred Stock and warrants, building on AIM’s existing $100 million shelf capacity. Historically, offering news has produced sizable moves, with an average change of 30.25%. Investors may track subscription uptake, any extensions to the February 2026 timetable, and progress of Ampligen trials, given the stated use of proceeds for clinical and manufacturing needs and partial debt repayment.

Key Terms

rights offering, subscription right, convertible preferred stock, warrants, +4 more

8 terms

rights offering financial

"regarding its proposed rights offering (the “Rights Offering”) and the expected"

A rights offering is a way for a company to raise additional money by giving existing shareholders the opportunity to buy more shares at a discounted price before they are offered to the public. It’s similar to a special sale where current owners get the first chance to buy extra items at a lower cost, allowing them to increase their investment if they choose. This process matters to investors because it can affect the value of their holdings and their ability to buy new shares at favorable terms.

subscription right financial

"one non-transferable subscription right (a “Subscription Right”) to purchase one unit"

A subscription right is a short‑term entitlement given to existing shareholders that lets them buy additional shares at a set price before the shares are offered to the public. Like a limited-time coupon to buy more of a product, it matters to investors because exercising the right can prevent ownership from being diluted and may offer a discounted chance to increase holdings, while selling the right can provide immediate cash if they don’t want more shares.

convertible preferred stock financial

"one share of Series G Convertible Preferred Stock (the “Preferred Stock”) and warrants"

Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.

warrants financial

"Preferred Stock (the “Preferred Stock”) and warrants to purchase 1,492 shares of Common"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

over-subscription privilege financial

"The Rights Offering will include an over-subscription privilege which permits each holder"

An over-subscription privilege is a feature of a share offering that lets existing investors request more shares than their initial entitlement, with any extra allocation given only if other investors do not take their full allotment. It matters because it gives shareholders a chance to increase their stake and avoid losing ownership percentage, much like ordering extra slices at a party in case others pass—however, receiving the extras is not guaranteed.

registration statement regulatory

"A registration statement (Registration No. 333- 292085) relating to these securities"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

prospectus regulatory

"The Rights Offering, which is expected to commence following the effectiveness of the registration statement, is being made only by means of a written prospectus."

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

dealer-manager financial

"Maxim Group LLC is acting as the dealer-manager in connection with the Rights Offering."

A dealer-manager is the lead broker or firm that organizes and runs a securities offering, coordinating other dealers, setting up the sale, marketing the issue to investors, and handling order allocation and settlement. Think of it as the project manager for a new issue: its effectiveness affects how widely the offering is distributed, the fees charged, and how smoothly investors can buy or sell the securities, so investors watch the dealer-manager for potential conflicts, pricing quality, and execution reliability.

AI-generated analysis. Not financial advice.

OCALA, Fla., Jan. 23, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, announced today an informational update to its security holders regarding its proposed rights offering (the “Rights Offering”) and the expected key dates and terms relative to the Rights Offering. Assuming that the Rights Offering is fully subscribed, the Company will receive gross proceeds of $12 million, less expenses related to the Rights Offering.

The Company is distributing to all holders of record of its common stock, par value $0.001 (the “Common Stock”), and to holders of certain options and warrants that have the right to participate in the Rights Offering (the “Participating Securities”), as of 5:00 p.m., Eastern Time, on February 4, 2026  (the “Record Date”), for each share of the Common Stock and each Participating Security, one non-transferable subscription right (a “Subscription Right”) to purchase one unit, at a subscription price of $1,000 per unit.  Each unit consists of one share of Series G Convertible Preferred Stock (the “Preferred Stock”) and warrants to purchase 1,492 shares of Common Stock (the “Warrants”). Each share of Preferred Stock will be convertible, at the option of the holder at any time, into a number of shares of Common Stock equal to the quotient of the stated value of the Preferred Stock ($1,000) divided by the conversion price (initially, $1.34 per share). Each Warrant will be exercisable for one share of Common Stock at an exercise price of $1.34 per share from the date of issuance through its expiration five years from the date of issuance. The Preferred Stock and the Warrants will separate upon the expiration of the Rights Offering and will be issued separately but may only be purchased as a subscription, and the subscriptions will not trade as a separate security. The subscriptions will not be tradable.

The Subscription Rights will be non-transferable and may only be exercised during the anticipated subscription period of Thursday, February 5, 2026 through 5:00 PM ET on Monday, February 23, 2026, unless extended by AIM.

The expected calendar for the Rights Offering is as follows:

• February 3, 2026: Ownership Day – in order to be considered a stockholder of record on February 4, 2026, shares should be acquired by this date (open market purchases of Common Stock should be completed by February 3 to be considered a stockholder of record on the Record Date). 
• February 4, 2026: Record Date (5:00 p.m. Eastern Time)
• February 5, 2026: Distribution Date; Subscription Period Begins
• February 23, 2026: Subscription Period Ends 5:00 p.m. Eastern Time

The Rights Offering will include an over-subscription privilege which permits each holder of Subscription Rights that exercises such holder’s basic Subscription Right in full to purchase additional subscriptions (if any) that remain unsubscribed at the expiration of the Rights Offering. The availability of the over-subscription privilege will be subject to certain terms and restrictions set forth in the prospectus. If the aggregate subscriptions (basic subscriptions plus over-subscriptions) exceed the number of subscriptions offered in the Rights Offering, then the aggregate over-subscription amount will be pro-rated among the holders exercising their respective over-subscription privileges (in proportion to the number of subscriptions held after giving effect to all basic subscriptions).

Certain of AIM’s leadership have indicated to the Company on a non-binding basis that they intend to participate in the Rights Offering, including Board member and Chief Executive Officer Thomas K. Equels.

The Company intends to use the net proceeds from the exercise of subscriptions for general corporate purposes – including clinical trial expenses and manufacturing expenses associated with prospective Phase 2/3 pancreatic cancer trials – and allocate a portion of the net proceeds to repay, according to their terms, certain existing debt obligations.

The Rights Offering will expire at 5:00 p.m., Eastern Time, on Monday, February 23, 2026, unless it is extended or earlier terminated by the Company, If the Company elects to extend the Rights Offering, it will issue a press release announcing the extension no later than 9:00 a.m., Eastern Time, on the next business day after the most recently announced expiration date of the Rights Offering. The Company may extend the Rights Offering for additional periods in its sole discretion for any reason up to an additional 45 days. Once made, all exercises of subscriptions are irrevocable.

The Company expects that Broadridge Corporate Issuer Solutions, LLC, the information agent for the Rights Offering, will mail rights certificates and a copy of the prospectus for the Rights Offering to holders of record of Common Stock and Participating Securities as of the Record Date beginning on or about February 5, 2026. Holders of securities held in “street name” through a brokerage account, bank or other nominee will not receive physical rights certificates and must instruct their broker, bank or other nominee whether to exercise Subscription Rights on their behalf. For any questions or further information about the Rights Offering, please call Broadridge Corporate Issuer Solutions, LLC, the information agent for the Rights Offering, at (855) 793-5068 or via email at Shareholder@Broadridge.com.

Neither the Company nor its Board of Directors has made or will make any recommendation to holders regarding the exercise of subscriptions. Holders should make an independent investment decision about whether or not to exercise their subscriptions based on their own assessment of the Company’s business and the Rights Offering.

A registration statement (Registration No. 333- 292085) relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. The Rights Offering, which is expected to commence following the effectiveness of the registration statement, is being made only by means of a written prospectus. A preliminary prospectus relating to and describing the proposed terms of the Rights Offering has been filed with the SEC as a part of the registration statement and is available on the SEC's website at https://www.sec.gov/. Copies of the preliminary and final prospectuses for the Rights Offering may be obtained, when available, from Maxim Group LLC, 300 Park Avenue, 16^th Floor, New York, NY 10022, Attention Syndicate Department, email: syndicate@maximgrp.com or telephone (212) 895-3745.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Maxim Group LLC is acting as the dealer-manager in connection with the Rights Offering.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in the press release speak only as of the date of the press release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. The Company is in various stages of seeking to determine whether Ampligen® will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders and disclosures in our reports filed with the Securities and Exchange Commission (“SEC”) on our website and in our press releases set forth our current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, we cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among the studies are clinical trials that provide only preliminary data with a small number of subjects, and no assurance can be given that the findings in these studies will prove true or that the study or studies will yield favorable results. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in our reports filed with the SEC, on the Company’s website and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

Please review the “Risk Factors” section in the Company’s latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. Its filings are available at www.aimimmuno.com. The information found on the Company’s website is not incorporated by reference herein and is included for reference purposes only.

Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

FAQ

What is the Record Date for the AIM (AIM) rights offering?

The Record Date is February 4, 2026 at 5:00 p.m. Eastern Time.

How much can AIM raise in the rights offering (AIM)?

If fully subscribed, AIM can receive gross proceeds of up to $12.0 million before expenses.

What does one unit in AIM's rights offering include?

Each $1,000 unit includes one Series G convertible preferred share and warrants for 1,492 common shares.

What are the conversion and exercise prices in the AIM rights offering?

The initial preferred conversion price is $1.34 per share and each warrant exercise price is $1.34 per share.

When can AIM shareholders exercise Subscription Rights for AIM (AIM)?

The anticipated subscription period runs from February 5, 2026 through February 23, 2026 at 5:00 p.m. ET.

How will AIM use the net proceeds from the rights offering?

Proceeds are intended for general corporate purposes, including clinical and manufacturing expenses for prospective Phase 2/3 pancreatic cancer trials and partial debt repayment.